Guangzhou Today, China Tomorrow? A Closer Look At Reimbursement Pilots For Iressa, Tarceva
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca CEO Pascal Soriot sees tremendous potential for Iressa in China, where Roche’s Herceptin grew over 20% in 2012. Both companies have their high-priced targeted therapies in China’s first-ever reimbursement pilot in Guangzhou.